DR Congo receives 70,000 Ebola vaccine doses as Bundibugyo outbreak spreads

DR Congo received 70,000 doses of the Ebola vaccine Ervebo as the Bundibugyo outbreak continues to expand, according to a recent announcement. The shipment follows a request from the government in Kinshasa for assistance from the global Ebola vaccine stockpile. The International Coordinating Group (ICG) approved the delivery, marking a critical step in addressing the growing crisis. The Bundibugyo outbreak, declared on May 15, has become the deadliest in DR Congo's history. As of Wednesday, the total number of confirmed cases reached 5,021, with over 2,325 fatalities recorded. Local authorities have not yet updated these figures since Monday, but the data released indicates a rapid escalation in infections. More than 160 healthcare workers have been infected, and 40 have succumbed to the virus. These numbers highlight the severity of the situation and the urgent need for intervention. The World Health Organization (WHO) expressed cautious optimism regarding the vaccine's potential effectiveness against the Bundibugyo strain of Ebola. While early laboratory and animal studies suggest some level of protection, the WHO emphasized that clinical trials are necessary to confirm these findings. The organization welcomed the allocation of the vaccine, noting that it represents a demonstration of global solidarity in combating public health emergencies. The ICG has decided to distribute 20,000 doses for a clinical trial in DR Congo, while allocating the remaining 50,000 doses to frontline health workers. Some residents in affected regions may also receive the vaccine outside the trial framework, though severe side effects are reported to be extremely rare based on previous clinical trials. WHO Director-General Tedros Adhanom Ghebreyesus praised the move, describing it as a significant example of international cooperation. The outbreak has been further complicated by the ongoing conflict in eastern DR Congo, where the Congolese government is engaged in a struggle with the Rwanda-backed M23 armed group and other factions. This conflict has impeded efforts to control the virus by obstructing access to conflict zones, leading to the destruction or closure of health facilities and the displacement of numerous individuals. These challenges make contact tracing and safe burial practices nearly impossible, exacerbating the spread of the virus. Despite the challenges posed by the conflict, the M23 group has claimed it can independently manage an Ebola response. According to reports, the group has established its own health administration, overseeing laboratories and asserting its capability to monitor disease outbreaks. On Thursday, the M23 reportedly announced a suspension of shared transportation services such as taxis and boats to and from government-controlled Ebola-affected areas, aiming to curb the virus's transmission within their territories. The United Nations has imposed sanctions on the M23 militia, condemning its actions against civilians, including forced conscription, mass killings, and sexual violence. These allegations are supported by numerous reports, investigations, and testimonies. Despite these tensions, the allocation of the vaccine offers a glimmer of hope for both the general population and frontline healthcare workers in the region. The ICG has previously distributed 56,000 doses of the Ervebo vaccine to address multiple Ebola outbreaks in DR Congo between 2021 and July 2026. UN Senior Ebola Coordinator Julien Harneis expressed his support for the latest allocation, stating that it provides hope for all those impacted by the outbreak, particularly for those working on the front lines. The continued distribution of the vaccine underscores the international community's commitment to mitigating the impact of the current crisis.